-
MyChart
Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
-
Request an Appointment
Request an Appointment
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information - Donate Today
Study #2016-0713
A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia
Study Status
Closed
Treatment Agent
Principal Investigator
Farhad Ravandi-Kashani
Description
The goal of this clinical research study is to find the highest tolerable dose of SEL24 that can be given to patients with acute myeloid leukemia (AML). Researchers want to learn more about the safety and potential effects of this study drug. This is the first study using SEL24 in humans.
General Information
Treatment Location: N/A
Sponsor: N/A
Study Status
IRB Review and Approval Date: 01/11/2017
Recruitment Status: Closed
Projected Accrual: N/A
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Study phase:
Phase I/Phase II
Physician name:
Farhad Ravandi-Kashani
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789